Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.49 |
| ▸ | CNR2 | P34972 | 12/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835758 | 0.98 | CNR1 (0.51) | CNR1CNR2MAPTSMN1; SMN2MEN1 | |
| SCHEMBL25849055 | 0.88 | GAA (0.44) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL18874911 | 0.82 | TDP1 (0.54) | CA12CA1CA2CA9 | |
| SCHEMBL16524095 | 0.82 | FAAH (0.50) | CNR1CNR2CA12CA1CA2 | |
| SCHEMBL26032408 | 0.82 | FAAH (0.50) | CNR1CNR2CA12CA1CA2 | |
| SCHEMBL28843534 | 0.82 | FAAH (0.50) | CNR1CNR2CA12CA1CA2 | |
| SCHEMBL25835507 | 0.82 | FAAH (0.50) | CNR1CNR2CA12CA1CA2 | |
| SCHEMBL23475931 | 0.81 | FAAH (0.49) | CNR1CNR2CA12CA1CA2 | |
| SCHEMBL32680127 | 0.81 | FAAH (0.49) | CNR1CNR2CA12CA1CA2 | |
| SCHEMBL23475914 | 0.81 | FAAH (0.49) | CNR1CNR2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CNR1 4510/4885CNR2 4584/4885MAPT 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.